Thu, Jul 24, 2014, 9:23 AM EDT - U.S. Markets open in 7 mins.

Recent

% | $
Click the to save as a favorite.

Amarin Corporation plc Message Board

  • coumery coumery Jul 8, 2013 10:18 PM Flag

    Akanz-Read Ihub board and feel like you made most sense...

    What to clarify your position - they are raising 100 million to stay in business through Reduce it, if Anchor is not be approved without Reduce It results?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hi Coumery
      I expect Anchor to be approved and will increase the scrips written /income produced to cover some of their costs ...BUT many MD's will not prescribe until they see convincing clinical benefit hopefully provided by the Reduce it trial results .
      So imagine if you are running this company .
      The gold ring is a positive results from the Reduce it trial -----that changes everything --proof of clinical benefit in reducing heart attacks in a US population ----without that you have expensive "fish oil "
      So , how do you survive until then because Reduce It results IS the final show down.

      They apparently can't make a deal to co launch Anchor ....so they get Anchor approved and don't expand marketing and sales for that cohort ? Once approved they must move forward and will be in a race of cash burn vs income coming in ...they must have modeled this a thousand way ...all of which say raise $ now.

      By the way ...there are very few CV drugs out there PROVEN to reduce heart attacks in a US population...
      so Reduce it results will be closely watched.
      I agree with JL in the following--expect early results, maybe by late 2014 early 2015
      JMO
      AK

      • 3 Replies to akanz2
      • Dr.Barry Sears is optimistic on Reduce-It results.He wished that they had used 6 gram/day dosage for best results.He believes inflammation reduction prevents CV events.He uses AA/EPA ratio.
        For Jelis,AA/EPA dropped from 1.6 to 0.8. However Americans have much higher AA/EPA ratio--or much higher C-RP.

        Sentiment: Buy

      • AK.......

        So JZ couldn't sell the company following approval although he implied to shareholders that
        he was going to attempt do so and we had serious interest from BP......

        Then he couldn't get a partner to help launch Vascepa here in the U.S.

        Then he couldn't get a partner to launch Vascepa in Europe or Asia.

        Then he borrows 100 million for a 150 million dollar payback to launch Vascepa on a GIA plan, and most of that is used up already about a year later.. Now a 150 million dollar secondary at $5ish that could have been done from $12 on down in the past year or so.

        Apparently JZ cannot find a partner now to help launch Anchor even if that is approved.

        Ditto no partner to help fund "Reduce It" which is the savior trial for this company although no other
        "fish oil" company has had positive compelling data thus far to prove that pure EPA reduces CV events in large scale clinical trials.

        That Officers have sold over 25 million dollars worth of their own stock since approval and haven't bought back any shares since then, even at $5?

        The positives? At least no one has talked about NCE in awhile!

        LOL JL...."JZ is a great CEO". I guess if you were short! LOL!

      • Coumery ...quick follow up ---say you have 24 months to Reduce it Results --July 2015 ---model a cash flow survival till then givin rate of scrip growth , expenses , loan payments etc ----you can be down to your last $100 when the results come out ... if Vascepa shows clinical benefit in reducing heart attacks you have a block buster drug ...if not ..well thats biotech
        AK

    • 100 million is only good for 2 quarters or half a year. They are getting by on days. What company can survive on that?

      Sentiment: Sell

 
AMRN
1.58+0.05(+3.16%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
General Motors Company
NYSEWed, Jul 23, 2014 4:01 PM EDT
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT